Aclaris (ACRS) witnessed a jump in share price last session on above-average trading volume. The lat

Gainers Alzamend Neuro (NASDAQ:ALZN) stock increased by 12.9% to $1.35 during Tuesday's after-m

U.S. stock futures mixed. SL Science shares fall 11.4% after reporting financial results. Other stoc

Top Wall Street analysts begin coverage of Aclaris Therapeutics, Orion Group Holdings, and Take-Two

Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.15) per share which met the anal

Piper Sandler analyst Biren Amin maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Overweight a

Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Cit

Guggenheim analyst Seamus Fernandez initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with

Wedbush analyst Martin Fan maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform and ra

"These results validate that ATI-052 is a highly potent and well tolerated bispecific antibody t

Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on deve

Oppenheimer analyst Jeff Jones initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with a Ou

Wedbush analyst Martin Fan reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform and m

- Participants with Atopic Dermatitis Receiving ATI-2138 Experienced Improvements in Key Clinical Me

Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on deve

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS)

Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.16) per share which missed the a

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS)

Aclaris Therapeutics reported early study results showing its ATI-2138 drug drove rapid and lasting

- ATI-2138 Outperforms Ritlecitinib in Reversal Model of Alopecia Universalis, the Most Severe AA Ph

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS)

Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial Reinforce

Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.12) per share which beat the ana

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS)

Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on deve

- Late Breaking Abstract to Present Additional Data from Aclaris' Phase 2a Trial of ATI-2138 in

U.S. stock futures rose on Wednesday after ending lower on Tuesday. Futures of major benchmark indic

Aclaris Therapeutics Inc (NASDAQ: ACRS) surgged 21.94% in after-hours trading on Tuesday after posi

WAYNE, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-s

Piper Sandler analyst Biren Amin assumes Aclaris Therapeutics (NASDAQ:ACRS) with a Overweight rat

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS)

Shares of WD-40 Company (NASDAQ: WDFC) rose sharply during Wednesday’s session after the company rep

Companies Reporting Before The Bell • HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 pe

Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) jumped 99% to $1.3195 after the company announ

  On Monday, 36 companies set new 52-week lows.

Upgrades

    Thursday morning saw 168 companies set new 52-week highs.

  Stocks That Hit 52-Week Highs On Monday Before 10 a.m. ET on Monday, 136 companies hit new 52-we